


Catalog #10-4412

ARN25499

N-(3,4-Dimethoxyphenyl)-4-phenyl-6-(piperidin-4-yl)pyrimidin-2-amine

Lot # FBA9217



ARN25499 is a novel CDC42 GTPase interaction inhibitor. It inhibits the interaction between CDC42 and its downstream effectors (i.e PAK) instead of the CDC42-GEF interaction. ARN25499 displayed activity against four melanoma cancer cell lines (IC₅₀s: SKM28 13.5 μM, SKMeI3 8.1 μM, WM3248 12.8 μM, A375 9.7 μM) and one colon cancer line (IC₅₀ = 11.2 μM SW480). It also displayed good pharmacokinetics in mice. ARN25499 also showed *in vivo* efficacy in melanoma PDX tumors in NSG mice @ 10mg/kg.

- 1) Brindani *et al.* (2024), *Discovery of CDC42 Inhibitors with a Favorable Pharmacokinetic Profile and Anticancer In Vivo Efficacy*, J. Med. Chem. **67** 10401

PHYSICAL DATA

Molecular Weight:	390.49
Molecular Formula:	C ₂₃ H ₂₆ N ₄ O ₂
Purity:	99% (HPLC)
	NMR: (Conforms)
Solubility:	DMSO (30 mg/mL)
Physical Description:	Yellow solid
Storage and Stability:	Store as supplied at -20°C for up to 2 years from the date of purchase. Solutions in DMSO may be stored at -20°C for up to 3 months.

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications.

Focus Biomolecules LLC 400 Davis Drive, Suite 600 Plymouth Meeting PA 19462

www.focusbiomolecules.com